| GR00016-A | 5595 | 5595 | MAPK3 | np | 1.47 | none | | no | | Wnt/beta-catenin pathway regulation | Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. | James et al. | 2009 | 19471023 | Cell line | RKO | Wnt/beta-catenin pathway reporter | Luminescence | rp | Selected genes | siRNA | Z-score | > 2 | | GR00053-A | 5595 | NM_002746 | MAPK3 | np | sp | Increased gamma-H2AX phosphorylation | | no | group 1 | Genome stability | A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. | Paulsen et al. | 2009 | 19647519 | Cell line | HeLa | gamma-H2AX phosphorylation and DNA content | Fluorescence | siARRAY human genome siRNA library | Genome-wide | siRNA | p-value | Complex criteria | Confidence groupings from 4 to 1 (highest level of confidence in group 4) | GR00054-A | 5595 | NM_002746 | MAPK3 | np | 1.068 | none | | no | | Combinatorial effect with paclitaxel | Synthetic lethal screen identification of chemosensitizer loci in cancer cells. | Whitehurst et al. | 2007 | 17429401 | Cell line | NCI-H1155 | Viability (synthetic lethal) | ATP level | # G-005000-01 | Genome-wide | siRNA | Paclitaxel/control ratio | Complex criteria | Additional information about 87 high-confidence hits | | 5595 | 5595 | MAPK3 | np | np | Increased cell migration | | yes | deconvoluted validated siRNAs: 1/4 | | | | | | | | | | | | | | | | GR00055-A-3 | 5595 | 5595 | MAPK3 | np | np | Increased cell migration | | no | | Epithelial cell migration (3) | Identification of genes that regulate epithelial cell migration using an siRNA screening approach. | Simpson et al. | 2008 | 19160483 | Cell line | MCF-10A overexpressing ERBB2 | Cell migration and viability | Microscopy and fluorescence | SMARTpool siRNA library and MAR library | Selected genes | siRNA | Area score and Alamar score | Complex criteria | | GR00056-A | 5595 | NM_002746 | MAPK3 | np | 1.025 | none | | no | | Melanogenesis | Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. | Ganesan et al. | 2008 | 19057677 | Cell line | MNT-1 | Melanin protein expression and viability | Absorbance and luminescence | rp | Genome-wide | siRNA | Normalized absorbance ratio | > 2 standard deviations below mean | Additional information about a secondary screen (retest to determine false-positive rate) | GR00057-A-1 | 5595 | NM_002746 | MAPK3 | M-003592-02 | 0.37 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 5595 | NM_002746 | MAPK3 | M-003592-02 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00095-A | 5595 | BC013992 | MAPK3 | np | np | none | | | | p53 pathway components | A large-scale RNAi screen in human cells identifies new components of the p53 pathway | Berns et al. | 2004 | 15042092 | Cell line | BJ-TERT-tsLT fibroblasts | Proliferation | Colony-forming cell assay | Nki library | Genome-wide | shRNA | np | np | | GR00098-A-1 | 5595 | ENSG00000102882 | MAPK3 | ENSG00000102882 | sp | none | | no | | Cell division (1) | Genome-scale RNAi profiling of cell division in human tissue culture cells. | Kittler et al. | 2007 | 17994010 | Cell line | HeLa | Cell number and DNA content | Laser scanning cytometry | rp | Genome-wide | esiRNA | Complex, sp | Complex criteria | | GR00114-A | 5595 | | MAPK3 | np | 1.29 | none | | | 91% | Combinatorial effect with Poly (ADP‐ribose)‐polymerase‐1 (PARP) | A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. | Turner et al. | 2008 | 18388863 | Cell line | CAL51 | Viability | Luminescence | siARRAY SMARTpool | Kinases | siRNA | Z-score | < | Growth rates (%) for vehicle-alone experiments are given in the comment field. | GR00123-A | 5595 | BC013992 | MAPK3 | 101563, 101561, 101562 | np | none | | | | Combinatorial effect with nutlin-3 | An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors | Brummelkamp et al. | 2006 | 16474381 | Cell line | MCF-7 | Viability | Fluoresence | Nki library | Genome-wide | shRNA | log2 ratio | np | | GR00133-A-1 | 5595 | 5595 | MAPK3 | np | -0.108035 | none | | no | | Salmonella enterica subspecies 1 serovar Typhimurium invasion (1) | RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. | Misselwitz et al. | 2011 | 21407211 | Cell line | HeLa | Gentamycin protection invasion assay | Fluorescence | Druggable genome library V2.0 | Druggable genes | siRNA | log2 median | Complex criteria | | GR00143-A | 5595 | | MAPK3 | MAPK3 s1 | sp | none | | no | | tau phosphorylation | High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. | Azorsa et al. | 2010 | 20067632 | Cell line | H4 overexpressing 4RON tau | Total tau and 12E8 tau protein expression | Fluorescence | Validated human kinase siRNA Set 2.0 | Kinases | siRNA | p-value | Complex criteria | | GR00143-A | 5595 | | MAPK3 | MAPK3 s2 | sp | none | | no | | tau phosphorylation | High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. | Azorsa et al. | 2010 | 20067632 | Cell line | H4 overexpressing 4RON tau | Total tau and 12E8 tau protein expression | Fluorescence | Validated human kinase siRNA Set 2.0 | Kinases | siRNA | p-value | Complex criteria | | GR00149-A-1 | 5595 | 5595 | MAPK3 | 142304 | -35.75 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5595 | 5595 | MAPK3 | 142304 | -35.57 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5595 | 5595 | MAPK3 | 202320 | 53.96 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5595 | 5595 | MAPK3 | 202320 | 58.52 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5595 | 5595 | MAPK3 | 214749 | -20.68 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5595 | 5595 | MAPK3 | 214749 | 35.27 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00151-A-1 | 5595 | ENSG00000102882 | MAPK3 | np | 0.932 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. | Słabicki et al. | 2010 | 20613862 | Cell line | HeLa | (HR-DSBR) DR-GFP reporter | Flow cytometry | Custom-made | Genome-wide | esiRNA | Z-score | < -2 OR > 2 | | GR00155-A | 5595 | 5595 | MAPK3 | MAPK3_1, MAPK3_2, MAPK3_3 | np | none | | no | | Aryl hydrocarbon receptor (AhR) transduction pathway regulation | RNAi-based screening identifies kinases interfering with dioxin-mediated up-regulation of CYP1A1 activity. | Gilot et al. | 2011 | 21479225 | Cell line | MCF-7 | TCDD-induced CYP1A1-related EROD activity and cell viability | Fluorescence and methylene blue | MISSION siRNA Human Kinase Panel library | Kinases | siRNA | Z-score | Top 150 for > | | GR00156-A | 5595 | | MAPK3 | np | 0.25 | Decreased telomerase activity | | yes | | Telomerase activity regulation | High-throughput RNAi screening reveals novel regulators of telomerase. | Cerone et al. | 2011 | 21531765 | Cell line | HeLa | Telomerase activity | Real-time qTRAP | SMARTpool siRNA kinase library | Kinases | siRNA | Percentage | < 35 % OR > 150 % | | GR00156-A | 5595 | | MAPK3 | np | 1.39 | Decreased telomerase activity | | yes | | Telomerase activity regulation | High-throughput RNAi screening reveals novel regulators of telomerase. | Cerone et al. | 2011 | 21531765 | Cell line | HeLa | Telomerase activity | Real-time qTRAP | SMARTpool siRNA kinase library | Kinases | siRNA | Percentage | < 35 % OR > 150 % | | GR00179-A-1 | 5595 | | ERK1 | np | 0.154 | Decreased viability with paclitaxel | | yes | | Combinatorial effect with paclitaxel (1) | RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. | Bauer et al. | 2010 | 20576088 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | pGIPZ shRNAmir plasmid library | Selected genes | shRNA | Sensitivity index | > 0.078 (> 3 shRNAs) OR > 0.15 (< | | GR00179-A-2 | 5595 | | ERK1 | np | np | none | | no | | Combinatorial effect with paclitaxel (2) | RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. | Bauer et al. | 2010 | 20576088 | Cell line | MDA-MB-231 | Viability (synthetic lethal) | Alamar Blue | Custom-made | Selected genes | siRNA | Sensitivity index | Complex criteria | | GR00179-A-3 | 5595 | | ERK1 | np | 0.148 | Decreased viability with paclitaxel | | no | | Combinatorial effect with paclitaxel (3) | RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. | Bauer et al. | 2010 | 20576088 | Cell line | MDA-MB-468 | Viability (synthetic lethal) | Alamar Blue | Custom-made | Selected genes | siRNA | Sensitivity index | Complex criteria | | GR00180-A-1 | 5595 | 5595 | MAPK3 | PL-50002 | 0.902 | none | | no | | Hepatitis C virus replication (1) | A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. | Tai et al. | 2009 | 19286138 | Cell line | Huh7/Rep-Feo | HCV replicon RNA copy number | Luminescence | siARRAY Human Genome siRNA Library | Genome-wide | siRNA | q-value | Complex criteria | | GR00184-A-1 | 5595 | NM_002746 | MAPK3 | M-003592-02 | -0.851250753601868 | none | | no | | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00193-A-1 | 5595 | 5595 | MAPK3 | MAPK3 | 0.302585752528102 | Decreased substrate adherent cell growth | | yes | Illumina gene expression above basal level (p < 0.05) | Therapeutic kinase targets in neuroblastoma (1) | RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. | Cole et al. | 2011 | 21289283 | Cell line | EBC1 | Substrate adherent cell growth | rp | Kinase siGenome library | Kinases | siRNA | Relative growth | 0.5 standard deviations below mean | | GR00193-A-2 | 5595 | 5595 | MAPK3 | MAPK3 | 0.67726310519917 | Decreased substrate adherent cell growth | | yes | Illumina gene expression above basal level (p < 0.05) | Therapeutic kinase targets in neuroblastoma (2) | RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. | Cole et al. | 2011 | 21289283 | Cell line | KELLY | Substrate adherent cell growth | rp | Kinase siGenome library | Kinases | siRNA | Relative growth | 0.5 standard deviations below mean | | GR00193-A-3 | 5595 | 5595 | MAPK3 | MAPK3 | 0.753570494749767 | Decreased substrate adherent cell growth | | yes | Illumina gene expression above basal level (p < 0.05) | Therapeutic kinase targets in neuroblastoma (3) | RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. | Cole et al. | 2011 | 21289283 | Cell line | SKNAS | Substrate adherent cell growth | rp | Kinase siGenome library | Kinases | siRNA | Relative growth | 0.5 standard deviations below mean | | GR00193-A-4 | 5595 | 5595 | MAPK3 | MAPK3 | 0.887 | none | | yes | Illumina gene expression above basal level (p < 0.05) | Therapeutic kinase targets in neuroblastoma (4) | RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. | Cole et al. | 2011 | 21289283 | Cell line | NLF | Substrate adherent cell growth | rp | Kinase siGenome library | Kinases | siRNA | Relative growth | 0.5 standard deviations below mean | | GR00196-A-1 | 5595 | ENSG00000102882 | | np | sp | none | | no | | TP53 interactions (1) | A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. | Krastev et al. | 2011 | 21642980 | Cell line | HCT116 ( wildtype and TP53 knockout) | TP53 protein expression and viability | Fluorescence | rp | Genome-wide | esiRNA | Complex, sp | Complex criteria | | GR00197-A-1 | 5595 | 5595 | MAPK3 | M-003592-02 | -0.93948788 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | GR00206-A | 5595 | 5595 | MAPK3 | np | np | none | | no | siRNA toxicity | Apoptosis regulation after Chlamydia trachomatis serovar L2 infection | HIF-1α is involved in mediating apoptosis resistance to Chlamydia trachomatis-infected cells. | Sharma et al. | 2011 | 21824245 | Cell line | HeLa | Cleaved cytokeratin-18 protein expression | Fluorescence | Custom-made | Apoptosis, cellular trafficking and cell signalling genes | siRNA | p-value | < | Author-reviewed data | GR00210-A | 5595 | 5595 | MAPK3 | np | sp | Decreased focal adhesion (FA) abundance, increased cell elongation, decreased cell spreading | | yes | clusters: MC-NE, DC4, CC3 | Focal adhesion formation | Multiparametric analysis of focal adhesion formation by RNAi-mediated gene knockdown. | Winograd-Katz et al. | 2009 | 19667130 | Cell line | HeLa | paxillin protein expression | Fluorescence | SMARTpool siARRAY siRNA Libraries | Kinases, phosphatases and selected genes | siRNA | Z-score | > 3.5 OR < -3.5 | | GR00221-A-1 | 5595 | | MAPK3 | TRCN0000006152 | -0.51 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-1 | 5595 | | MAPK3 | TRCN0000006150 | 0.14 | none | | yes | | Proliferation of cells with active beta-catenin (1) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MCF-7 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 5595 | | MAPK3 | TRCN0000006150 | -0.83 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-2 | 5595 | | MAPK3 | TRCN0000006152 | 0.59 | none | | yes | | Proliferation of cells with active beta-catenin (2) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-231 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 5595 | | MAPK3 | TRCN0000006152 | 0.11 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-3 | 5595 | | MAPK3 | TRCN0000006150 | 0.46 | none | | yes | | Proliferation of cells with active beta-catenin (3) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | MDA-MB-453 | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 5595 | | MAPK3 | TRCN0000006150 | -1.99 | Decreased viability | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00221-A-4 | 5595 | | MAPK3 | TRCN0000006152 | 0 | none | | no | | Proliferation of cells with active beta-catenin (4) | CK1epsilon is required for breast cancers dependent on beta-catenin activity. | Kim et al. | 2010 | 20126544 | Cell line | T47D | Viability | Luminescence | TRC shRNA Library | Kinases | shRNA | B-score | < -1 | Essential gene: gene with B-score < -1 for > | GR00225-A | 5595 | | MAPK3 | MAPK3_A | -1.12206 | none | 10nM gemcitabine | no | | Combinatorial effect with gemcitabine | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. | Azorsa et al. | 2009 | 19519883 | Cell line | MIAPaCa-2 | Viability (synthetic lethal) | Luminescence | Validated kinase siRNA library version 1.0 | Kinases | siRNA | log2 ratio | 1.65 SD below mean ratio level | | GR00225-A | 5595 | | MAPK3 | MAPK3_B | -1.04761 | none | 10nM gemcitabine | no | | Combinatorial effect with gemcitabine | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. | Azorsa et al. | 2009 | 19519883 | Cell line | MIAPaCa-2 | Viability (synthetic lethal) | Luminescence | Validated kinase siRNA library version 1.0 | Kinases | siRNA | log2 ratio | 1.65 SD below mean ratio level | | GR00225-A | 5595 | | MAPK3 | MAPK3_A | -0.104435 | none | 5nM gemcitabine | no | | Combinatorial effect with gemcitabine | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. | Azorsa et al. | 2009 | 19519883 | Cell line | MIAPaCa-2 | Viability (synthetic lethal) | Luminescence | Validated kinase siRNA library version 1.0 | Kinases | siRNA | log2 ratio | 1.65 SD below mean ratio level | | GR00225-A | 5595 | | MAPK3 | MAPK3_B | 0.033925 | none | 5nM gemcitabine | no | | Combinatorial effect with gemcitabine | Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. | Azorsa et al. | 2009 | 19519883 | Cell line | MIAPaCa-2 | Viability (synthetic lethal) | Luminescence | Validated kinase siRNA library version 1.0 | Kinases | siRNA | log2 ratio | 1.65 SD below mean ratio level | | | 5595 | NM_002746 | MAPK3 | np | 0.748786 | none | | no | | | | | | | | | | | | | | | | | GR00231-A | 5595 | NM_002746 | MAPK3 | M-003592-02 | -0.161 | none | | yes | | Cell proliferation | Time-resolved human kinome RNAi screen identifies a network regulating mitotic-events as early regulators of cell proliferation. | Zhang et al. | 2011 | 21765947 | Cell line | HeLa | Viability | Electrical impedance | Human siARRAY - Protein Kinase and Cell Cycle libraries | Kinases and selected genes | siRNA | Z-score | < -1.96 OR > 1.96 | Additional information about cell titer blue cell viability screen | GR00234-A-1 | 5595 | NM_002746 | MAPK3 | np | sp | none | | no | | Hepatitis C virus (HCV) infection (1) | EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. | Lupberger et al. | 2011 | 21516087 | Cell line | Huh7 | Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) protein expression | Luminescence | Human Kinase RNAi Set V2.0 | Kinases | siRNA | Complex, sp | Complex criteria | | GR00236-A-1 | 5595 | 5595 | MAPK3 | M-003592-02 | 1.27763265246809 | none | | no | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | GR00240-S-1 | 5595 | NM_002746 | MAPK3 | M-003592-02 | -0.64 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-2 | 5595 | NM_002746 | MAPK3 | M-003592-02 | 0.29 | none | | no | Z-score -0.372 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00242-A-1 | 5595 | NM_002746 | MAPK3 | np | np | none | | no | | Selective autophagy regulation (1) | Image-based genome-wide siRNA screen identifies selective autophagy factors. | Orvedahl et al. | 2011 | 22020285 | Cell line | HeLa/GFP-LC3 | Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression | Fluorescence | siGenome | Genome-wide | siRNA | Z-score | Complex criteria | | GR00247-A-1 | 5595 | | MAPK3 | np | sp | none | | | rank: 17118 | Regulation of FOXO1 nuclear localization (1) | Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. | Senapedis et al. | 2011 | 21460183 | Cell line | U2OS | EGFP-FOXO1a protein expression and DNA content | Fluorescence | Human Genome library | Genome-wide | siRNA | Complex, sp | Complex criteria | | GR00248-A | 5595 | NM_002746 | MAPK3 | MAPK3_siRNA1 | -2.414 | Decreased human cytomegalovirus (HCMV) strain AD169 replication | | | | Human cytomegalovirus (HCMV) strain AD169 replication | Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. | Terry et al. | 2012 | 22315427 | Cell line | MRC5 | Human cytomegalovirus (HCMV) IE1 protein expression | Fluorescence | Mission siRNA Human Kinase Panel | Kinases | siRNA | Z-score | > | | GR00248-A | 5595 | NM_002746 | MAPK3 | MAPK3_siRNA2 | 0.504 | none | | | | Human cytomegalovirus (HCMV) strain AD169 replication | Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. | Terry et al. | 2012 | 22315427 | Cell line | MRC5 | Human cytomegalovirus (HCMV) IE1 protein expression | Fluorescence | Mission siRNA Human Kinase Panel | Kinases | siRNA | Z-score | > | | GR00248-A | 5595 | NM_002746 | MAPK3 | MAPK3_siRNA3 | 0.224 | none | | | | Human cytomegalovirus (HCMV) strain AD169 replication | Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. | Terry et al. | 2012 | 22315427 | Cell line | MRC5 | Human cytomegalovirus (HCMV) IE1 protein expression | Fluorescence | Mission siRNA Human Kinase Panel | Kinases | siRNA | Z-score | > | | GR00249-S | 5595 | 5595 | MAPK3 | J-003592-07 | 0.1705 | none | | no | number of cells compared to control (%): 65.01 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 5595 | 5595 | MAPK3 | M-003592-03 | 0.29478 | none | | no | number of cells compared to control (%): 69.93 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 5595 | 5595 | MAPK3 | s11140 | -1.87575 | Decreased vaccinia virus (VACV) infection | | no | number of cells compared to control (%): 75.80 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 5595 | 5595 | MAPK3 | s11141 | 0.27375 | none | | no | number of cells compared to control (%): 73.16 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 5595 | 5595 | MAPK3 | s11142 | -0.40257 | none | | no | number of cells compared to control (%): 80.83 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00250-A-1 | 5595 | 5595 | MAPK3 | M-003592-02 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (1) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Genome-wide | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5595 | 5595 | MAPK3 | D-003592-02 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | duplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5595 | 5595 | MAPK3 | D-003592-02 | sp | none | | | sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5595 | 5595 | MAPK3 | D-003592-06 | sp | none | | | duplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5595 | 5595 | MAPK3 | D-003592-06 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5595 | 5595 | MAPK3 | D-003592-19 | sp | none | | | duplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5595 | 5595 | MAPK3 | D-003592-19 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5595 | 5595 | MAPK3 | D-003592-01 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | duplicate screen, sextuplicate screen; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-3 | 5595 | 5595 | MAPK3 | D-003592-01 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 5595 | 5595 | MAPK3 | D-003592-02 | sp | none | | | 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 5595 | 5595 | MAPK3 | D-003592-02 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 5595 | 5595 | MAPK3 | D-003592-06 | sp | Synthetic lethal with MLN4924 (a NAE inhibitor) | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 5595 | 5595 | MAPK3 | D-003592-19 | sp | none | | | 116 nM MLN4924, 91 nM MLN4924; set: Top240; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00253-A | 5595 | NM_002746 | MAPK3 | np | -1.295 | none | | | | hepcidin regulation | Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. | Mleczko-Sanecka et al. | 2014 | 24385536 | Cell line | Huh7 | hepcidin::fluc mRNA expression | Luminescence | siGenome siARRAY SMARTpool | Genome-wide | siRNA | Z-score | > | Cutoff < | GR00255-A-1 | 5595 | 5595 | MAPK3 | TRCN0000006150, TRCN0000006151, TRCN0000006152, TRCN0000010997, TRCN0000010998 | 0.823342456 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 5595 | 5595 | MAPK3 | TRCN0000006150, TRCN0000006151, TRCN0000006152, TRCN0000010997, TRCN0000010998 | 0.091070929 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 5595 | 5595 | MAPK3 | TRCN0000006150, TRCN0000006151, TRCN0000006152, TRCN0000010997, TRCN0000010998 | 1.093888123 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 5595 | 5595 | MAPK3 | TRCN0000006150, TRCN0000006151, TRCN0000006152, TRCN0000010997, TRCN0000010998 | -0.100545027 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 5595 | 5595 | MAPK3 | TRCN0000006150, TRCN0000006151, TRCN0000006152, TRCN0000010997, TRCN0000010998 | 1.219851992 | none | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00256-A | 5595 | NM_002746 | MAPK3 | np | sp | none | | | | Kinase-mediated spindle orientation | ABL1 regulates spindle orientation in adherent cells and mammalian skin. | Matsumara et al. | 2012 | 22252550 | Cell line | HeLa | beta-tubulin protein expression and DNA content | Fluorescence | Silencer Kinase siRNA library (AM80010V3) | Kinases | siRNA | Complex, sp | Complex criteria | HeLa cells stably expressing GFP-H2B (HeLa-GH2B) used. Additional information about secondary screens. | GR00293-A | 5595 | | MAPK3 | np | 0.835 | none | | | | Combinatorial effect with paclitaxel | Mechanisms Promoting Escape from Mitotic Stress−Induced Tumor Cell Death | Sinnott et al. | 2014 | 24860162 | Cell line | HCC366 | Viability | Luminescence | Thermo-Fisher | Genome-wide | siRNA | Z-score | < -2.5 | Final hits according to the author are indicated in the comment. | GR00300-A | 5595 | | MAPK3 | TRCN0000006150, TRCN0000010998, TRCN0000006151, TRCN0000006152, TRCN0000010997 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00303-A | 5595 | NM_002746 | MAPK3 | np | 0.01 | none | | | | Clear cell renal cell carcinoma (ccRCC) survival regulation | Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target | Gerlinger et al. | 2012 | 22362593 | Cell line | VHL-deficient RCC4 | Proliferation and Viability | Fluorescence | np | Genome-wide | siRNA | Z-score | < | In the phenotype data duplicates were in the original document, which have been removed. | GR00306-A | 5595 | 5595 | MAPK3 | np | 40.71 | Decreased human papilloma virus 16 (HPV16) pseudovirus infection | | | | Human papillomavirus 16 (HPV16) infection | Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus | Lipovsky et al. | 2013 | 23569269 | Cell line | HeLa-S3 | HPV16 pseudovirus reporter | Fluorescence | Dharmacon SMARTpool | Genome-wide | siRNA | Modified activity score (MAS1) | Top 1000 | | GR00310-A-1 | 5595 | 5595 | MAPK3 | np | -1.58 | none | | | | Sindbis virus (SINV) infection (1) | Genome-Wide RNAi Screen Identifies Novel Host Proteins Required for Alphavirus Entry | Ooi et al. | 2013 | 24367265 | Cell line | U2OS | Sindbis virus (SINV) reporter | Luminescence | Ambion Silencer V3 | Genome-wide | siRNA | Z-score | < -3 OR > 2 | | | 5595 | 5595 | MAPK3 | np | -10.1 | none | | | 126,1% viability | | | | | | | | | | | | | | | | GR00313-A | 5595 | NM_001040056, NM_002746 | MAPK3 | np | 0.47 | none | | | | TNF-alpha pathway regulation | A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. | Nickles et al. | 2012 | 22733992 | Cell line | HEK293T | NFkappaB pathway reporter | Luminescence | Qiagen | Genome-wide | siRNA | Z-score | < | Additional filters were a reduction in firefly luciferase levels by at least 50% compared to the mean of the experiment and a concomitant reduction of renilla luciferase expression of not more than 30%. | GR00318-A | 5595 | 5595 | MAPK3 | np | 1.023 | none | | | siRNA set: kinase | Huntingtin toxicity | A Genome-Scale RNA–Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington’s Disease | Miller et al. | 2012 | 23209424 | Cell line | HEK293T | Caspase 3/7 activity | Fluorescence | Dharmacon | Selected genes | siRNA | Sum of normalized caspase 3/7 activity mean and standard error | < 0.683 | HEK293T cells were cotransfected with mutant Huntingtin fused to GFP (Htt1-558141Q-GFP). | GR00342-S-1 | 5595 | | MAPK3 | M-003592-02 | 0.3837285051749837 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (1) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 1, MSC preparation 1 (MSC1a) | GR00342-S-2 | 5595 | | MAPK3 | M-003592-02 | 0.2721508668657848 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (2) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 1, MSC preparation 2 (MSC1b) | GR00342-S-3 | 5595 | | MAPK3 | M-003592-02 | 0.961814444313421 | none | | | | Viability of Mesenchymal Stem Cells (MSC) (3) | Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening | Erdmann et al. | 2015 | 26120366 | Primary cells | Bone marrow derived MSC | Viability | Luminescence | Kinase siGENOME SMARTpool library | Kinases and phosphatases | siRNA | Z-score | > | Donor 2, MSC preparation 1 (MSC2) | GR00343-S | 5595 | 5595 | MAPK3 | TRCN0000006151 | 0.6150000000000002 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 5595 | 5595 | MAPK3 | TRCN0000006152 | 0.7099999999999991 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 5595 | 5595 | MAPK3 | TRCN0000006150 | -2.5975 | shRNA abundance <= 25% | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | | 5595 | | MAPK3 | np | 1 | Resistant to vaccinia virus (VACV-A4L) infection | | | | | | | | | | | | | | | | | | | GR00360-A-1 | 5595 | | MAPK3 | 142305 | -1.3579 | Increased CFP-tsO45G cell surface transport | | | | Secretory transport (1) | Genome-wide RNAi screening identifies human proteins with a regulatory function in the early secretory pathway | Simpson et al. | 2012 | 22660414 | Cell line | HeLa Kyoto | CFP-tsO45G cell surface transport | Fluorescence | Ambion | Genome-wide | siRNA | Deviation score | < - 1 OR > 0.75 (mild: 0.75 - 1.0; strong: > 1.0) | For validation screen see Secretory transport (2). | GR00362-A | 5595 | 5595 | MAPK3 | np | np | Synthetic lethal with vaccinia virus (VACV) infection | | | | Vaccinia virus (VACV) replication | A loss of function analysis of host factors influencing Vaccina virus replication by RNA interference | Beard et al. | 2014 | 2401222 | Cell line | HeLa | VACV-A5eGFP expression | Fluorescence | SMARTpools, Dharmacon | Genome-wide | siRNA | Z-score | < | Genes were prescreened for viability, those declared as lethal were not screened for fluorescence. | | 5595 | 5595 | MAPK3 | | 0.06000000000000001 | none | | | | | | | | | | | | | | | | | | | GR00371-A-1 | 5595 | 5595 | MAPK3 | | 0.311687683206 | none | | | Dharmacon | Nanog expression in absence of bFGF and TGFbeta | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-2 | 5595 | MAPK3 | 5595 | | 0.080590000022 | none | | | Dharmacon | Nanog expression in presence of TGFbeta inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-3 | 5595 | 5595 | MAPK3 | | 0.37502017352 | none | | | Dharmacon | Nanog expression in presence of MEK inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-4 | 5595 | 5595 | MAPK3 | | 0.447786787328 | none | | | Dharmacon | Nanog expression in presence of PI3K inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-5 | 5595 | 5595 | MAPK3 | | -0.511797458759 | none | | | Dharmacon | Nanog expression in presence of retinoic acid | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00376-A-1 | 5595 | 5595 | MAPK3 | | 0.388241793 | none | | | | Mitigators of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID | GR00376-A-2 | 5595 | 5595 | MAPK3 | | 0.191298191 | none | | | | Sensitizers of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID | GR00378-A | 5595 | | MAPK3 | | -1.113431297 | none | | | | Poliovirus vaccine production | Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game | van der Sanden et al. | 2015 | 26581994 | Cell line | HEp-2C | Infection with Attenuated Poliovirus | ELISA | Dharmacon | Genome-wide | siRNA | Z-score | > | For infection, a single lot of the attenuated Sabin type 2 poliovirus was used for the screen. Gene IDs were not provided, only the gene name/symbol | | 5595 | NM_002746 | MAPK3 | | 59.283 | none | | | | | | | | | | | | | | | | | | | GR00386-A-1 | 5595 | 5595 | MAPK3 | | 123.67701409842 | Increased viability | | | | NOD2 stimulation by MDP | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | Viability | Luminescence | Dharmacon | Genome-wide | siRNA | Percentage growth | Decreased: <70, increased: >120 | Reagent IDs not provided | GR00386-A-2 | 5595 | 5595 | MAPK3 | | -102.7 | none | | | | MDP-induced IL-8 secretion | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | IL-8 secretion | ELISA | Dharmacon | Genome-wide | siRNA | Percent inhibition of IL-8 secretion | Increased: <-300, Decreased: >60 | Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |